肝癌筛查新指标：异常凝血酶原（PIVKA-II） - 知乎专栏
异常凝血酶原（PIVKA-II）是维生素K缺乏或拮抗剂-II诱导的蛋白质，可出现于维生素K缺乏或肝细胞肝癌（HCC）患者的血清中，是诊断HCC的另一个重要指标，可与AFP互为补充。 多数研 …
PIVKA-II is a useful tool for diagnostic characterization of ultrasound ...
Protein induced by vitamin K absence-II (PIVKA-II) is a potential screening marker for hepatocellular carcinoma (HCC). Limited data are available about its utility in discriminating …
PIVKA-II serves as a potential biomarker that complements AFP …
2023年4月13日 · PIVKA-II is a promising serum biomarker for the HCC diagnosis that can be used as a supplement for AFP. The combined diagnosis of the two markers greatly improved …
PIVKA-II as a Potential New Biomarker for Hepatocellular Carcinoma - A ...
PIVKA-II achieved the best sensitivity (96.9%) in distinguishing between the HCC and control groups with the proposed cut-off value of 60 mAU/ml. Conclusion: Our recommendation is for …
异常凝血酶原（Pivka-II）指标的解读 | 中山大学肿瘤防治中心
2021年6月28日 · 近年来，新的肝癌指标－异常凝血酶原（Pivka-II）进入我们的视野。 Pivka-II是血液凝固因子的第II因子体，在肝细胞癌中出现特异性上升。 为与AFP无关的辅助标记物，在 …
The clinical application of PIVKA‐II in hepatocellular carcinoma …
2021年9月30日 · Protein induced by vitamin K absence or antagonist-II (PIVKA-II), also known as des-gamma carboxyprothrombin (DCP), was first introduced as a novel HCC biomarker in …
异常凝血酶原（PIVKA-II）与原发性肝细胞肝癌（HCC） - 知乎
pivka-ii（异常凝血酶原）不仅应用于早期肝癌的诊断，并且可应用于外科手术的疗效评估。外科根治术后，pivka-ii水平降低并维持低水平者，术后复发风险显著降低，虽然afp手术前后的变化 …
Performance of PIVKA-II for early hepatocellular carcinoma …
Background & aims: Prothrombin induced by vitamin K absence-II (PIVKA-II) is a diagnostic and surveillance marker for HCC mainly used in Asia, and has also been shown to be a predictor …
肿瘤标志物科普系列--异常凝血酶原（PIVKA-II）升高原因分析
异常凝血酶原（PIVKA-II）是维生素K缺乏或拮抗剂-II诱导的蛋白质，可出现于维生素K缺乏或肝细胞肝癌（HCC）患者的血清中，是诊断HCC的另一个重要指标，可与AFP互为补充。 我国目 …
PIVKA-II as a Potential New Biomarker for Hepatocellular …
PIVKA-II was first described as a new biomarker in 1996 and has been used since the beginning of the 21st century. This pilot study represents the first study conducted in the Czech Republic …